BioMarin May Be On Cusp Of Profitability, With GALNS The Key Determining Factor
This article was originally published in The Pink Sheet Daily
At the Canaccord Genuity Global Growth Conference, the rare disease-focused biotech reiterated its goal to reach profitability in the near future with five pipeline programs potentially augmenting a portfolio of four marketed products.
You may also be interested in...
To maintain a stable supply of some multinational products for patients with rare diseases, the health ministry has extended its pilot refund system for three more years until 2015.
BioMarin is in the midst of a pivotal year, with several near-term data catalysts, the most important of which will be Phase III data on GALNS for the rare disease MPS IV.
CNS specialist Neuraxpharm has struck a deal with Israel’s Panaxia to market medical cannabis products in Europe, starting in Germany.